Updates

** Shares of telehealth firm Hims & Hers Health HIMS.N slump 14.6% to $24.90, snapping a two-day winning streak

** Stock set for its biggest percentage drop in over three months, if losses hold

** Co missed Q1 revenue estimates and posted an unexpected loss, as its move into branded GLP-1 weight-loss drugs squeezed margins and hurt U.S. sales

** Co posted Q1 sales of $608.1 million, below analysts' estimates of $616.85 million - LSEG-compiled data

** Co reported a Q1 loss of 40 cents/share, compared with analysts' estimate for a profit of 4 cents/share

** J.P. Morgan trims PT to $33 from $35; maintains an "overweight" stance on the stock

** Brokerage sees that the shift from compounded to Novo-branded GLP-1s was going to create noise in the near-term financials

** Adds that this lends weight to concerns that the shift to branded products could weigh on co's margin profile

** As of last day's close, stock down 10.25% YTD